Drive Oncology Discovery
Gene expression analysis is a key tool to understand the interactions and pathways that lead to cancer and how to disrupt them with treatment strategies. With over 100 different types of cancer, the appropriate treatment is not always simple to select, so identifying responders and non-responders is critical to patient survival.
The nCounter platform from offers an extensive catalog of oncology panels to study gene expression changes in patient samples, the tumor microenvironment, and immune responses due to cancer.
Covering both the adaptive and innate immune systems, this panel is a complete tool to study immune response in cancer. Included in the targets are genes from 24 immune cell types, common checkpoint inhibitors, CT antigens, and genes for immune response. The most run oncology panel, it offers a powerful look at the immune response to cancer.
Because metastatic disease is a primary cause of death in cancer patients, drugs that inhibit metastatic transition or slow metastasis are greatly needed. The PanCancer Progression panel targets 770 genes that look at critical aspects of cancer progression, allowing researchers to assess efficacy of anti-metastatic compounds in pre-clinical models.
The Breast Cancer 360 oncology panel provides a unique complete view of gene expression for the breast tumor microenvironment and immune response to assess immunotherapy efficacy. Researchers can decode the complexities of breast cancer biology, develop novel breast cancer signatures with TIS and PAM50 analysis, and categorize disease heterogeneity.
Ideally suited for new CAR-T development and QC, this panel measures 8 essential components of CAR-T biology in 780 genes and facilitates the development of robust product release assays with a streamlined workflow goaled at reducing vein-to-vein time. Developed in partnership with industry experts, this panel is the gold standard assay for development, manufacturing, and delivery of CAR-T cell therapies.
The only gene expression panel built to study tumors and immune responses in dogs, this 800 target oncology panel takes advantage of tumor-specific coverage for the most common canine cancers. With overlapping content with the PanCancer IO360 and PanCancer Immune Profiling Panels, researchers can apply their findings from spontaneous canine cancers to human health and potentially improve clinical trial success.
Ideal for immuno-oncology and translational researchers, this panel covers potentially clinically actionable genes and signatures. Use this panel to help you understand the mechanisms of immune evasion in the tumor and predict responses to immune-targeted therapies. Part of the 360 oncology panel series, it provides a comprehensive view of gene expression and incorporates the Tumor Inflammation Signature (TIS).
Part of the PanCancer family of panels, the PanCancer Pathways panel allows you to conduct multiplex gene expression analysis from 13 canonical cancer-associated pathways. Measure treatment effects on pathways, screen samples for biomarker discovery, and study pathway deregulation with end-to-end analysis.
This oncology panel covers genes involved in tumorigenesis, metastasis, and inflammation, offering a holistic view of 40+ pathways involved in tumor biology, immune evasion, and remodeling of the microenvironment. The panel emphasizes dysfunctional cell signaling and can be used to identify targets for novel therapies. Study the mechanisms of action of current therapies and access the TIS for clinically relevant gene signatures.
Guide development of your Antibody Drug Conjugate (ADC) from discovery to the clinic. This panel is composed of 770 genes profiling immune response, ADC internalization and payload release, cell death, mechanisms of resistance, and both traditional and emerging MOAs.
Quantify the expression of hundreds of genes involved in core metabolic processes and signaling pathways in the context of cancer and immunity. The underlying molecular mechanisms behind alterations in metabolic pathways, signaling pathways, and cell stress can now be fully elucidated, giving researchers a complementary tool to traditional metabolite assays for profiling metabolic checkpoints and discovering potential therapeutic targets.
Access Clinically-Relevant Gene Expression Signatures
We are one of only five nCounter service providers that offer nAlgorithm™ gene signature reporting for biopharma clinical studies. We offer the Tumor Inflammation Signature (TIS), Lymphoma Subtyping Test (LST), and PAM50 assay. These signatures provide cell typing and quantification, assist in patient stratification, and facilitate better biomarker identification.
A Turnkey Solution for Gene Expression Analysis
Our nCounter service is streamlined and efficient, with three simple steps to deliver reproducible data for your study.
Select Your Gene Panel
Choose from one of the predesigned gene panels relevant to your research, customize it with a spike in, or design your own.
Tell Us About Your Samples
Provide the sample number, sample type and species, and we will take care of the rest. We can also isolate RNA from your blood, cell pellets, or tissue samples.
We Deliver Your Data
We include raw and normalized data in your nCounter service. We also offer premium data analysis packages through ROSALIND for differential gene expression analysis.
Your Partner in Cancer Research
We offer a comprehensive suite of services applicable to cancer research. By partnering with us, you can see the entire cellular landscape by detecting and quantifying a virtually unlimited number of biomarkers in tumor microenvironments while maintaining high resolution spatial information using our CellScape™ Precise Spatial Proteomics technology.
Gain comprehensive, unbiased gene expression information with our RNA-Seq and single-cell RNA-Seq capabilities or generate spatial transcriptomic profiling using GeoMx® digital spatial profiling and CosMx™ spatial molecular imaging technologies. Leveraging this suite of powerful platforms will result in deeper understanding of cancer biology, immune responses, treatment efficacy, and tumor microenvironments.
Additional nCounter Panels
Immunology and Infectious Disease
The Immunology and Infectious Disease Panels are designed for researchers studying autoimmunity, immune responses to infectious diseases, and changes in immune cell populations in oncology contexts.
Specialized Applications
The Specialized Application Panels support a range of focused research topics including cardiovascular disease, neuroscience, stem cell technologies, microRNA, and gene therapies.
Frequently Asked Questions
Yes - if you choose to analyze your data through ROSALIND, we will provide comprehensive training upon data delivery to help you confidently analyze your data. As the expert in your samples and study, we encourage you to lead the analysis. While we can help support you, we don't provide it as a service outside of our partner ROSALIND. To learn more about how we can help, contact us. We also offer the TIS, DLBCL and PAM50 gene signatures for clinically relevant gene expression analysis.
nCounter is a powerful technique for gene expression profiling and highly successful and reproducible in most sample types including formalin-fixed paraffin-embedded (FFPE) tissue, crude -cell lysates and blood. We can do the RNA isolation for you or you can send us your purified total RNA.